On August 4, Stevanato Group (NYSE:STVN) reported second-quarter revenue of €302.0 million, up 8% year over year, while also closing the sale of its California-based subsidiary, Balda C. Brewer Inc. The results paired steady growth in the company’s core drug containment and delivery business with a portfolio move that reshaped its bottom line for the quarter. High-value solutions, the products Stevanato has been building its future around, made up 45% of total revenue. That combination of growth and restructuring sets up the rest of the story.
High-Value Products Take The Lead
The Biopharmaceutical and Diagnostic Solutions segment, Stevanato’s largest, grew revenue 9% to €266.2 million, or 10% at constant currency rates. Inside that segment, high-value solutions revenue jumped 16% to €135.9 million, pushed mainly by high-performance syringes and EZ-fill vials, and that mix shift is what carried company-wide profitability higher. Gross profit margin rose 60 basis points to 28.7%, and adjusted EBITDA margin climbed 280 basis points to 26%. Adjusted net profit grew 20% to €37.6 million, and adjusted diluted earnings per share rose to €0.14 from €0.11 in the same quarter last year.
The Engineering segment also became more profitable, with gross margin up 540 basis points to 12%, helped by an ongoing business optimization plan and a stronger project mix out of the company’s Danish operations. On top of the financial improvement, a customer also won regulatory clearance across several European markets for a liraglutide treatment that uses Stevanato’s Alina pen injector platform, a milestone for the company’s drug delivery ambitions. The Balda C. Brewer sale, completed June 30, is expected to be accretive to full-year margins, even though the subsidiary had been projected to bring in about €30 million of revenue in fiscal 2026.
A Divestiture Leaves Its Mark
The Engineering segment, Stevanato’s smaller division, saw revenue fall 2% to €35.8 million, dragged down by weaker demand for glass converting and pharma visual inspection equipment that only partly offset growth in assembly and after-sales services. Management said it remains cautious about the segment given long sales cycles and shifting project timelines, even as the optimization plan gains traction. The Balda C. Brewer sale carried a real cost. The company booked €12.2 million in one-time expenses tied to the transaction, which pulled diluted earnings per share on a GAAP basis down to €0.08 and cut reported operating profit margin by 190 basis points to 12.9%.
Free cash flow was negative €32 million for the quarter, as €65.7 million was used for the purchase of property, plant, and equipment, and intangible assets outpaced €31.9 million in operating cash flow, while capital expenditures specifically totaled €52 million for new sites in Italy and Indiana and the Alina pen injector program in Germany. Net debt stood at €360.3 million against €78.6 million of cash on hand as of June 30. Full-year revenue guidance was also narrowed, with the top end trimmed to €1.280 billion from €1.290 billion previously, even as the update reflects the removal of Balda C. Brewer’s contribution.
Where Wall Street Money Sits
Hedge fund ownership of Stevanato Group fell to 18 funds in the most recent quarter from 21 previously, which points to some institutional money stepping back. Short interest sits at just 2.09% of the float, a level that suggests little organized skepticism toward the stock. The stock trades at 27.78 times forward earnings as of September 3, a multiple that already prices in continued growth from the high-value product mix. That combination of departing funds and a growth-priced multiple is the tension worth watching, even with short sellers largely staying on the sidelines.
What The Next Quarters Must Show
Stevanato Group closed its second quarter with faster growth in the business it says matters most, high-value solutions inside the BDS segment, while also shedding a smaller subsidiary that no longer fit its strategy. The Engineering segment’s revenue decline and the divestiture’s hit to GAAP earnings and free cash flow show the transition carries near-term costs. Continued growth in high-value solutions and progress on the Alina platform would keep the growth story intact.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Follow Insider Monkey on Google News.
Hedge Fund Resource Center